A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase I/IIa study designed to evaluate if experimental anti-PD-1 and anti-TIM-3
bispecific antibody, AZD7789 is safe, tolerable and efficacious in participants with advanced
solid tumors.